Lupin is an Indian pharmaceutical company established in 1968. It has a presence in over 100 markets worldwide and generates revenue through generic and branded formulations, APIs, and OTC products. In FY 2021, Lupin reported revenues of approximately $2.2 billion and net profits of $130 million. It focuses on therapeutic areas like cardiovascular, CNS, and respiratory drugs. Lupin emphasizes quality, compliance, ethics, and CSR initiatives while facing challenges from regulatory changes and competition in key markets like North America and Europe.

1. SUBJECT : ENTERPRISE ANALYSIS – DESK RESEARCH
P U N E D I S T R I C T E D U C A T I O N A S S O C I A T I O N ’ S
I N S T I T U T E O F T E C H N I C A L E D U C AT I O N R E S E A R C H A N D M A N A G E M E N T
A K U R D I P U N E - 4 1 1 0 4 4
Name of the Company :
GROUP ROLL NO. NAME
K
2023151 PATIL SHREYASH BABASAHEB
2023152 PATIL VAISHNAVI SANJAY
2023153 PAWADE RUSHIKESH SUNIL
2023124 PRAJAPATI SEEMA LALTAPRASAD
2023155 RAJIWADE ADITYA DATTATRAYA

2. INDEX
E n te r p r i s e H i s t o r y & B a c k g ro u n d 3
O rga n i z a t i o n 7
M a r ke t s 8
F i n a n c i a l s 1 0
G o v e r n a n c e 1 3
2

3. 3
E n t e r p r i s e H i s t o r y & B a c k g r o u n d
Lupin is an innovation-led transnational pharmaceutical
company. Patient-centricity is deep-rooted in our DNA and our values-
driven culture forms the bedrock of every interaction. We constantly work
towards our goal of making high-quality medicines affordable and
accessible to all – this is our path to a higher goal.
Our founder, Dr. Desh Bandhu Gupta (DBG), was committed
to improving the healthcare scenario in India. At a time when the
pharmaceutical industry in India was in nascent stages and most medicines
were being imported, DBG dreamt of placing the country on the global
pharmaceutical map. Driven by this passion, the company was established
in 1968 and named Lupin – a flower that not only grows and thrives in
harsh conditions but also nourishes the soil in which it is present.
Headquartered in Mumbai, India, today, Lupin has a strong
presence in more than 100 markets across the world. Our products range
from branded and generic formulations, biotechnology products, and
Active Pharmaceutical Ingredients (APIs) to Over-the-Counter (OTC)
products and Specialty pharmaceuticals.

4. 4
Mission & Value :

5. 5
CSR:
Indian pharmaceuticals major Lupin Limited has spent Rs 34.2 cr on Corporate Social Responsibility (CSR)
programmes during FY 2019-20.
The company broadly undertakes the following CSR activities:
 Economic Development
 Social Development
 Rural Infrastructure Development
 Natural Resource Management
 Learn and Earn programme and
 Disaster Relief and Mitigation

6. 6
Phylosophy:
Lupin's manufacturing philosophy is simple yet strategic — we consider the
needs and priorities of our key stakeholders to provide maximum impact. We are focused on
innovation, and the development of safe, effective life-saving drugs for our patients.
Quality Policy:
Lupin is committed to delivering high-quality medicines to patients and
customers across the globe. This commitment shines through in our focus on quality.
This improvement endeavour is further complemented by Lupin’s Corporate Quality
Assurance (CQA) cell’s continuous evaluations, which ensure strong linkage and knowledge
transfer between our quality, manufacturing and research teams. Over 700 CQA professionals work
across our manufacturing locations to develop and implement procedures aiming for the gold
standard in quality and compliance.

7. O R G A N I Z A T I O N
7

8. 8
M A R K E T S
8
1. Global Reach: Lupin Pharma is a multinational
pharmaceutical company that operates in several
key markets worldwide. The company has a strong
presence in North America, Europe, Asia, Africa,
and Latin America.
2. North American Market: Lupin has made
substantial inroads into the North American
pharmaceutical market, particularly in the United
States. It is one of the top generic drug
manufacturers in the U.S., with a diverse portfolio
of generic and branded products. Lupin's U.S.
headquarters is in Baltimore, Maryland.
3. Europe: Lupin also has a presence in the European
pharmaceutical market. It sells generic and branded
pharmaceuticals in various European countries.
4. India: As an Indian pharmaceutical company,
Lupin Pharma has a significant presence in its
home market, India. It serves the Indian market
with a wide range of pharmaceutical products,
including generics and branded medications.

9. 9
5. Research and Development: Lupin has a strong focus on research and development (R&D)
and invests heavily in developing new drugs and generic equivalents of existing medications.
The company has several research facilities globally, including in India, the United States, and
Europe.
6. Therapeutic Areas: Lupin Pharma operates in various therapeutic areas, including
cardiovascular, central nervous system, dermatology, gastrointestinal, respiratory, anti-infective,
and oncology. It has a diverse product portfolio, catering to a wide range of medical conditions.
7. Regulatory Approvals: To operate in different markets, pharmaceutical companies like Lupin
need to obtain regulatory approvals and meet the respective countries' healthcare standards.
Lupin has received numerous approvals from regulatory authorities such as the U.S. Food and
Drug Administration (FDA), the European Medicines Agency (EMA), and others.
8. Global Competition: Lupin competes with other global pharmaceutical companies in all the
markets it serves. Competition is intense in the pharmaceutical industry, with companies
constantly striving to develop new drugs and gain market share.
9. Market Challenges: The pharmaceutical industry is subject to various challenges, including
regulatory changes, pricing pressures, intellectual property issues, and the need for continuous
innovation. Lupin, like other pharmaceutical companies, faces these challenges as it operates in
various markets.

10. F I N A N C I A L S
10
1. Revenue: Lupin is one of the largest
pharmaceutical companies in India and has a
significant global presence. In the fiscal year
ending March 31, 2021, Lupin reported
consolidated revenues of around INR 16,369 crore
(approximately $2.2 billion USD).
2. Profitability: Lupin's profitability can vary from
year to year due to factors such as product
launches, generic competition, and regulatory
developments. In the same fiscal year mentioned
above, the company reported a consolidated net
profit of approximately INR 966 crore
(approximately $130 million USD).
3. Global Operations: Lupin generates a substantial
portion of its revenue from international markets,
with a focus on North America, Europe, and other
regions. Its performance in these markets can have
a significant impact on its financial results.

11. 11
4. Research and Development (R&D): Lupin has a robust R&D pipeline and invests heavily
in research and development to bring new drugs and generic products to the market. R&D
expenses are a substantial part of its operational costs.
5. Debt and Liabilities: Like many pharmaceutical companies, Lupin may have debt
obligations and other financial liabilities. The company's financial health can be influenced
by its ability to manage its debt and financial obligations effectively.
6. Share Performance: Lupin's stock performance on the Bombay Stock Exchange (BSE) and
the National Stock Exchange (NSE) of India can provide insights into the market's
perception of the company's financial health and prospects.
7. Regulatory Environment: The pharmaceutical industry is subject to stringent regulatory
oversight, and changes in regulations or product recalls can impact a company's financials.
Lupin, like other pharmaceutical firms, must navigate regulatory challenges.

12. 12

13. G O V E R N A N C E
13
1. Corporate Policies: Lupin Pharma has
established a set of corporate governance policies
and guidelines that govern its operations. These
policies encompass areas such as code of conduct,
insider trading policies, risk management, and
ethical business practices.
2. Transparency and Disclosure: The company is
committed to providing transparent and accurate
information to its shareholders and stakeholders.
This includes timely reporting of financial results,
disclosures of material information, and adherence
to all regulatory reporting requirements.
3. Shareholder Rights: Lupin Pharma recognizes
the importance of protecting the rights of its
shareholders. It communicates with shareholders
and encourages their active participation in
corporate decisions through general meetings.

14. 14
1.Risk Management: The company has systems in place for identifying, assessing, and
managing risks associated with its business operations. Effective risk management is crucial for
safeguarding the interests of shareholders and stakeholders.
2.Compliance and Ethics: Lupin Pharma places a strong emphasis on compliance with all
applicable laws and regulations. The company's commitment to ethical business practices is
reflected in its corporate culture and policies.
3.Sustainability and CSR: Like many modern corporations, Lupin Pharma is also focused on
its corporate social responsibility (CSR) initiatives. It undertakes various sustainable and
community development programs aimed at making a positive impact on society and the
environment.
4.Independent Auditors: The company engages independent audit firms to conduct regular
audits of its financial statements to ensure accuracy and adherence to accounting standards.

15. THANK YOU